ArticleCureus2025
Early Clinical Improvement With Lamotrigine Augmentation in Severe Treatment-Resistant Unipolar Depression: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treatment-resistant depression (TRD) is a major clinical challenge, with limited augmentation strategies beyond conventional antidepressants. Lamotrigine, an anticonvulsant licensed for bipolar depression, has been trialled in unipolar TRD, though evidence remains inconsistent, and its use is currently off-license. We describe a 45-year-old gentleman with severe TRD who failed multiple trials of antidepressants, including citalopram and mirtazapine in the community, and subsequently fluoxetine during admission following a suicide attempt. Given his lack of response, lamotrigine augmentation was initiated. Within three weeks, he demonstrated substantial improvement in mood, engagement, and self-care, alongside near-complete resolution of suicidal ideation. Depression severity, measured by the Patient Health Questionnaire-9 (PHQ-9), decreased from 23/27 (severe) to 3/27 (minimal) three weeks post lamotrigine. This rapid response occurred earlier than typically reported in clinical studies. The case highlights lamotrigine as a potentially valuable augmentation option in TRD and emphasises the need for further research to clarify its efficacy and predictors of early response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.